REC-4881 for Familial
Adenomatous Polyposis
New Phase 2 data presented at CGA-IGC show REC-4881 durably reduces larger, higher-risk polyps and highlights activity across the upper and lower GI in Familial Adenomatous Polyposis
LEARN HOW
Latest Data from Phase 2 Trial of REC-4881
Recursion announced new positive Phase 2 data from the ongoing TUPELO trial of REC-4881, an investigational, oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The new analyses show that most patients had reductions in both the number of larger, higher-risk polyps and lower GI polyp burden, and builds on the upper GI results announced on October 15. Read the press release →
Earnings call 3Q26
Phase 2 data read-out with Lisa Boardman, M.D.
Lisa Boardman, M.D., Professor of Medicine at Mayo Clinic and TUPELO investigator, presents updated Phase 1b/2 TUPELO results from the Presidential Plenary at the 2026 CGA-IGC Annual Meeting, including new analyses of larger polyps and lower GI polyp burden, safety, and a comparison with real-world registry data. REC-4881 is an investigational oral MEK1/2 inhibitor for FAP.
Phase 2 data recap with Najat Khan, Ph.D.
Najat Khan, Ph.D., President and CEO of Recursion, presents the REC-4881 update from the 3Q26 earnings webinar: unmet need in FAP, how Recursion's platform identified MEK1/2 inhibition, updated TUPELO results for total, upper GI and lower GI polyp burden at Weeks 13 and 25, Spigelman staging, and safety to prepare for a registrational trial in 2H 2027.
KOL panel
Evelien Dekker, M.D., Ph.D. (Amsterdam UMC) and Bryson Katona, M.D., Ph.D. (University of Pennsylvania) join Vicki Goodman, M.D., Chief Medical Officer of Recursion, to discuss the updated TUPELO data, the current management of FAP, and the role of upper and lower GI disease in post-colectomy patients.
Patient panel
Laura and Jesse Laster, and Lindsay Huff join Vicki Goodman, M.D., Chief Medical Officer of Recursion, to discuss their experiences with FAP, including surgery, ongoing surveillance and family planning, and their perspective on the updated TUPELO data.
